BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Microplasmin: Phase III data

In the double-blind, international Phase III TG-MV-007 trial in 326 patients, a single 125 µg intravitreal injection of microplasmin met the primary endpoint of significantly increasing the proportion of patients achieving non-surgical resolution of their focal VMA as measured by optical coherence tomography at day 28 vs. placebo (25.3% vs. 6.2%, p=0.001). In patients without epiretinal membrane, 34.5% of microplasmin-treated patients achieved resolution of their VMA at day 28 vs. 6.4%...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >